Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY
May 10 2023 - 12:15PM
Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a
biopharmaceutical company developing transformational therapies to
address significant global health challenges, today announced that
Blue Water management will present at the JMP Securities Life
Sciences Conference at the New York Hilton Midtown on Monday, May
15th at 3:30pm EDT.
Session details are as follows:
Date: |
Monday, May 15th, 2023 |
Time: |
3:30pm EDT |
Location: |
New York Hilton Midtown, Room
E |
Title: |
Blue Water Biotech Overview and
ENTADFI® Launch Plan |
At the conference, Blue Water management will present a
corporate overview and highlight its launch plan for ENTADFI®, an
FDA-approved treatment for benign prostatic hyperplasia (“BPH”)
that counteracts negative sexual side effects seen in men on
alternative BPH therapies.
“Following our purchase of ENTADFI® in April, we are excited to
share our launch strategy with the investment community,” said
Joseph Hernandez, Chairman and Chief Executive Officer of Blue
Water. “We believe ENTADFI® has the potential to transform the BPH
space and positively impact the lives of millions of men, and we
look forward to sharing our strategy with all in attendance.”
Blue Water management will be available during the conference
for one-on-one meetings. Interested parties may request a
one-on-one meeting at investors@bwbioinc.com or contact Blue Water
at (513) 620-4101.
About ENTADFI®
ENTADFI® is an oral, once daily treatment for BPH that combines
finasteride, a 5α-reductase inhibitor, and tadalafil, a
phosphodiesterase 5 (PDE5) inhibitor, offering a more effective
treatment option compared to other available therapies. Clinical
trials have shown that ENTADFI® is more effective in treating BPH
symptoms, including urinary frequency, urgency, weak stream, and
difficulty initiating or maintaining urination, compared to
finasteride monotherapy. Additionally, ENTADFI® has demonstrated a
favorable safety profile, with fewer adverse sexual side effects
compared to finasteride. ENTADFI® reduces potential for adverse
sexual side effects, making it a preferred choice for men seeking
relief from BPH symptoms without compromising their sexual health.
ENTADFI® has received FDA approval for the indication of initiating
treatment of the signs and symptoms of BPH in men with an enlarged
prostate for up to 26 weeks. More information about BPH and full
ENTADFI® prescribing information can be found on the product
website at https://entadfipatient.com/.
About Blue Water Biotech
Blue Water Biotech, Inc. is a biological and pharmaceutical
technology company focused on developing and providing
transformational therapies to address significant health challenges
globally. Headquartered in Cincinnati, OH, the Company holds the
rights to proprietary technology developed at the University of
Oxford, Cincinnati Children’s Hospital Medical Center, St. Jude
Children’s Hospital, and The University of Texas Health Science
Center at San Antonio. Blue Water is developing a Streptococcus
pneumoniae vaccine candidate, designed to specifically prevent
highly infectious middle ear infections, known as acute otitis
media (AOM), in children, and prevention of pneumonia in the
elderly. The Company is also developing a universal flu vaccine
that will provide protection from all virulent strains in addition
to licensing a novel norovirus (NoV) S&P nanoparticle versatile
virus-like particle (VLP) vaccine platform from Cincinnati
Children’s to develop vaccines for multiple infectious diseases,
including Marburg and monkeypox, among others. Additionally, the
Company is developing a Chlamydia vaccine candidate with UT Health
Science Center San Antonio to prevent infection and reduce the need
for antibiotic treatment associated with contracting Chlamydia
disease. Outside of its vaccine franchise, Blue Water owns
ENTADFI®, an FDA-approved, once daily pill that combines
finasteride and tadalafil for the treatment of benign prostatic
hyperplasia. This combination allows men to receive treatment for
their symptoms of BPH without the negative sexual side effects
typically seen in patients on finasteride alone. For more
information about Blue Water, visit www.bwbioinc.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on Blue Water’s current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, risks related to
Blue Water’s ability to realize the benefits of its acquisition of
ENTADFI®, risks related to BWV’s ability to expand its business
scope and its ability to commercialize ENTADFI®, risks related to
the development of Blue Water’s vaccine candidates; the failure to
obtain FDA clearances or approvals and noncompliance with FDA
regulations; delays and uncertainties caused by the global COVID-19
pandemic; risks related to the timing and progress of clinical
development of our product candidates; our need for additional
financing; uncertainties of patent protection and litigation;
uncertainties of government or third party payor reimbursement;
limited research and development efforts and dependence upon third
parties; and substantial competition. As with any vaccine under
development, there are significant risks in the development,
regulatory approval and commercialization of new products. Blue
Water does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in Blue Water’s Annual Report on Form 10-K, filed with
the Securities and Exchange Commission (the “SEC”) on March 9, 2023
and periodic reports filed with the SEC on or after the date
thereof. All of Blue Water’s forward-looking statements are
expressly qualified by all such risk factors and other cautionary
statements. The information set forth herein speaks only as of the
date thereof.
Media Contact Information:Blue Water Media
RelationsTelephone: (646) 942-5591 Email:
Nic.Johnson@russopartnersllc.com
Investor Contact Information:Blue Water Investor RelationsEmail:
investors@bwbioinc.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jul 2023 to Jul 2024